Loading...
Derniers dépôts
-
Aurélie Jourdes, Elise Cellerin, Cyrille Touzeau, Stéphanie Harel, Blandine Denis, et al.. Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study. Clinical Microbiology and Infection, 2024, 30 (6), pp.764-771. ⟨10.1016/j.cmi.2024.02.023⟩. ⟨hal-04916309⟩
-
F. Giugliano, A. Bertaut, J. Blanc, A. L. Martin, M. Fournier, et al.. Characteristics, treatment patterns and survival of patients with high-risk early hormone receptor-positive breast cancer in French real-world settings: an exploratory study of the CANTO cohort. ESMO Open, 2024, 9 (12), ⟨10.1016/j.esmoop.2024.103994⟩. ⟨hal-04831746⟩
-
Anna Patrikidou, Loïc Chaigneau, Nicolas Isambert, Kyriaki Kitikidou, Ryan Shanley, et al.. Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA). BMC Cancer, 2020, 20 (1), pp.117. ⟨10.1186/s12885-020-6548-6⟩. ⟨hal-02872774⟩
-
Vincent Rondeau, Maria Kalogeraki, Lilian Roland, Zeina Abou Nader, Vanessa Gourhand, et al.. CXCR4 signaling determines the fate of hematopoietic multipotent progenitors by stimulating mTOR activity and mitochondrial metabolism. Science Signaling, 2024, 17 (860), pp.eadl5100. ⟨10.1126/scisignal.adl5100⟩. ⟨hal-04786079⟩
-
Sauyeun Shin, Remy Nicolle, Christine Jean, Rémi Samain, Mira Ayadi, et al.. Translatome-based classification reveals a dual metabolic dependency of a new tumor subtype of pancreatic cancer. bioRxiv : the preprint server for biology, 2020, 12 (11), pp.1447-1454.e4. ⟨10.1101/2020.12.23.424227⟩. ⟨hal-04858439⟩
-
Camille Laurent, A Nicolae, C Laurent, F Le Bras, Corinne Haioun, et al.. JAK-STAT PATHWAY AND EPIGENETIC REGULATORS ARE CRITICAL PLAYERS IN BI-ALCL PATHOGENESIS?. International Conference on Malignant Lymphoma, 2019, Lugano, Switzerland. , Hematological Oncology, 37 (S2), pp.18-22, ⟨10.1002/hon.16_2630⟩. ⟨inserm-04831206⟩
-
Ingrid Masson, Laurène Larriviere, Marc-André Mahé, David Azria, Pascal Pommier, et al.. Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancer. Clinical and Translational Radiation Oncology, 2024, 44, pp.100702. ⟨10.1016/j.ctro.2023.100702⟩. ⟨hal-04813716⟩
-
Jean-Emmanuel Kurtz, Xavier Buy, Frédéric Deschamps, Erik Sauleau, Amine Bouhamama, et al.. CRYODESMO-O1: A prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment. European Journal of Cancer, 2021, 143, pp.78-87. ⟨10.1016/j.ejca.2020.10.035⟩. ⟨hal-03623642⟩
-
Nicolas Penel, Olivier Mir, Jennifer Wallet, Isabelle Ray-Coquard, Axel Le Cesne, et al.. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. European Journal of Cancer, 2020, 126, pp.45-55. ⟨10.1016/j.ejca.2019.12.001⟩. ⟨hal-03623680⟩
-
Yassine Al Tabaa, Rene Oliver Casasnovas, Clio Baillet, Emmanuel Bachy, Emmanuelle Nicolas-Virelizier, et al.. Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group. Blood Advances, 2023, 7 (14), pp.3735-3738. ⟨10.1182/bloodadvances.2023009911⟩. ⟨hal-04239554⟩
-
Francesco Fraioli, Nathalie Albert, Ronald Boellaard, Ilaria Boscolo Galazzo, Matthias Brendel, et al.. Perspectives of the European Association of Nuclear Medicine on the role of artificial intelligence (AI) in molecular brain imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 51 (4), pp.1007-1011. ⟨10.1007/s00259-023-06553-1⟩. ⟨inserm-04783173⟩
-
Franck Morschhauser, Loretta Nastoupil, Pierre Feugier, Jean-Marc Schiano de Colella, Hervé Tilly, et al.. Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R 2 ) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma. Journal of Clinical Oncology, 2022, 40 (28), pp.3239-3245. ⟨10.1200/JCO.22⟩. ⟨inserm-04783079⟩